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3 weeks according to protocol and consecutively underwent surgical re-
section. Radiological and metabolic response was measured by [18F]-
FDG-PET/CT after 3 and 21 days, and postoperatively the pathological 
response was assessed in the resection specimen. 
Results: Our patient had developed grade 2 skin toxicity in the third 
week of erlotinib treatment. Evaluation after 3 days and 21 days with 
[18F]-FDG-PET showed no appreciable metabolic response and stable 
disease on CT. A lobectomy of the right upper lobe with lymph node 
dissection was carried out. Pathological evaluation showed strong 
ﬁbrotic degeneration of the original tumor, with a vital rest of less 
than 10%. All lymph nodes were free of tumor. The low percentage of 
tumor cells did not allow for EGFR mutation analysis. There were no 
postoperative complications, and skin toxicity dissolved spontaneously 
after cessation of erlotinib.
Conclusions: In this patient with stage I adenocarcinoma of the right 
lung, receiving 3 weeks of preoperative erlotinib resulted in near com-
plete pathologic response. This result shows that erlotinib could be a 
potent agent in neoadjuvant and/or adjuvant setting in the treatment of 
non-small cell lung cancer.
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Background: Somatic mutations in the epidermal growth factor recep-
tor (EGFR) gene have been reported to be present in non-small-cell 
lung cancer, and associated with sensitivity of tumors to EGFR tyrosine 
kinase inhibitors. We previously reported on positive correlation of 
EGFR mutations with effectiveness of geﬁtinib treatment in 59 patients 
with recurrence after pulmonary resection (JCO, 23: 2513-2510, 2005). 
Here, we report the result of updated analysis based on 103 patients, 
adding 44 patients, with longer follow-up.
Methods: We sequenced exons 18-21 of the EGFR gene using total 
RNA extracted from 103 patients with lung cancer who were treated 
with geﬁtinib for their recurrent disease. Because this study was a retro-
spective analysis of clinical practice, the evaluation of tumor response 
could not be performed strictly according to Response Evaluation Cri-
teria in Solid Tumors. Therefore tumor response to geﬁtinib treatment 
was evaluated by both the imaging studies and the change in serum 
carcinoembryonic antigen (CEA). Geﬁtinib treatment was judged as 
effective when the tumors showed at least a 30% decrease in tumor 
diameter or when the elevated serum CEA level decreased to a level 
less than half of the baseline level.
Results: EGFR mutations were detected in 61 of 103 tumors (59%). Of 
them, 31 were exon 19 deletions, 22 were L858R, three were G719X, 
three were insertions in exons 19 or 20, and two were other types of 
point mutations. Mutations were signiﬁcantly frequent in female (72% 
in female, 48% in male) (P=0.0131, χ2 test), never-smokers (73% in 
never-smokers, 48% in former or current smokers) (P=0.0082), and the 
patients with adenocarcinomas (65% in adenocarcinomas, 17% in non-
adenocarcinomas) (P=0.0031). The response to geﬁtinib treatment was 
assessable in 88 patients, and 51 patients were evaluated as effective 
(the response rate (RR) was 58%). The RR in the patients with EGFR 
mutations was 83% (45 of 54 patients was effective), whereas the RR 
in those without mutation was 18% (6 of 34 patients was effective). 
Logistic regression analysis using various factors (sex, age, smoking 
status, histology, existence of prior chemotherapy, pathological stage, 
status of EGFR mutation) showed that EGFR mutation (odds ratio 
53.666, P<0.0001) and absence of prior chemotherapy (odds ratio 
5.979, P=0.0143) were signiﬁcant factors contributing to the response. 
Patients with EGFR mutation survived for a signiﬁcant longer period 
than those without mutations after geﬁtinib treatment (MST, 30.1 
versus 10.6 month; P=0.0038, log-rank test). When the patients with 
EGFR mutation were divided to subgroups according to the types of 
EGFR mutations, the RRs of each group were differed (93% in exon 19 
deletions, 75% in L858R, 67% in G719X, and 0% in exon 19 inser-
tion). However, there was no difference in overall survival after geﬁ-
tinib treatment between the patients with two major types of mutation 
(MST, 36.0 month in exon 19 deletions versus 33.1 month in L858R; 
P=0.7247).
Conclusions: We conﬁrmed that the tumors with EGFR mutations 
showed good correlation with clinical response to geﬁtinib treatment 
in patients with recurrent lung cancer after pulmonary resection in this 
updated analysis. Furthermore, we found that there were differences in 
the RR among the classes of mutations.
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Background: The current standard of care for advanced stage NSCLC 
is platinum-based doublet chemotherapy. Bevacizumab (BV) is a 
recombinant, humanized anti-vascular endothelial growth factor mono-
clonal antibody with proven efﬁcacy in cancer therapy. In advanced 
NSCLC, the addition of bevacizumab 15 mg/kg every 3 weeks to pacli-
taxel/carboplatin (PC) prolonged survival and progression-free survival 
(PFS), and improved PFS (survival data pending) when combined with 
cisplatin/gemcitabine (Sandler N Engl J Med. 2006, Genentech press 
release). 
Methods: In the present studies, we are using BV 15 mg/kg day 1 in 
combination with gemcitabine (G) 1000 mg/m2 days 1 and 8, and car-
boplatin (C) AUC5 day 1 for the treatment of NSCLC. Eligible pts with 
stage IIIB-IV NSCLC, PS 0-1, and adequate hematologic, renal and he-
patic function, have been enrolled. Pts with squamous cell carcinoma, 
tumor in the central airways, baseline hemoptysis, or brain metastases 
are excluded; IIIB pts had malignant effusion. GC/BV treatment was 
given in q 3-weekly cycles for 4- 6 cycles, with BV continued in stable 
and responding patients until progression. One of the studies was 
amended after 7 pts were enrolled to reduce the dose of G from 1250 
to 1000 mg/m2 on days 1 and 8 due to unacceptable neutropenia. Only 
data from patients treated after the dose reduction is presented. To date, 
17 pts in one trial and 12 pts in the other have received at least 2 cycles 
of combination therapy; we report here the hematologic and non-hema-
tologic toxicity of these pts. 
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Results: We have enrolled 13 men and 16 women, median age 65 years 
old. In 29 evaluable patients, only 1 episode of febrile neutropenia has 
been documented and was related to aspergillus pneumonia. Twenty of 
29 patients have developed grade 3/4 neutropenia (only 4 grade 4), all 
requiring dose reductions. Ten of 29 patients have developed grade 3/4 
thrombocytopenia, and an additional 11 of 29 had grade 1 or 2 throm-
bocytopenia. No signiﬁcant bleeding episodes have been documented, 
though grade 1/2 hemorrhoidal bleeding was documented in 4/29 and 
grade 1 hematuria occurred in 4/29 patients. Anemia has been mild 
with grade 3 anemia in only 5 of 29 patients. Non-hematologic toxicity 
was generally minor, with fatigue being the principal toxicity; adverse 
events possible related to BV include grade 3 hypertension and angina 
(1 pt), grade 1 hypertension (1 pt), perforated ulcer (1 pt) and epistaxis 
(grade 3 in 1 pt, grade 1 in 11 pts). No thrombosis has been reported 
and grade 1 proteinuria in only 1 patient. There have been no fatal 
toxicities. 
Conclusions: To date, the addition of BV to GC in pts with NSCLC is 
generally well tolerated, and toxicities have been expected and manage-
able. Enrollment is ongoing. 
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Background: It is apparent that there is a cluster of clinical factors that 
predict for an increased rate of response and survival to the epidermal 
growth factor (EGFR) tyrosine kinase inhibitors. However, the current 
knowledge of EGFR DNA mutations and gene expression is insuf-
ﬁcient to explain these observations. The purpose of this study is to 
enrich the population of patients more likely to respond to the EGFR 
inhibitor, erlotinib, and to perform extensive genomic screening to 
identify tumour-speciﬁc genome abnormalities to predict patterns of 
response and resistance. 
Methods: Eligibility criteria: stage IIIB/IV NSCLC; chemo-naive; ≥ 
1 measurable lesion; ECOG ≤2; adequate organ function; and at least 
2 of the following 4 criteria: women, never-smokers, Southeast Asian 
extraction, adenocarcinoma (ACA) and/or bronchioloalveolar carci-
noma. All patients must consent to a baseline fresh tumour biopsy and 
serum sample; biopsies during treatment and at disease progression are 
optional. Tumour cells are isolated by laser microdissection following a 
pathology review. Tumour genomic DNA is applied to high-resolution 
genomic microarrays to detect tumour-speciﬁc changes in copy number 
and/or genotype at multiple sites across the genome, including EGFR 
and exons encoding genes with altered copy number. Erlotinib 150mg 
p.o. daily is given on a continuous basis until disease progression.
Results: From Sept-06 to Feb-07, 20 patients (pts) have been enrolled. 
Median age 62 (range 43- 78); 17 females and 3 males; 18 never 
smokers, 2 former and 0 current smokers. PS 0-4; 1 - 13; 2 - 3. Ethnic-
ity: 5 Caucasian and 15 Asian (including China-7 & Hong Kong-3). 
Pathology: 17 ACA; 1 squamous carcinoma; 2 NSCLC NOS. As of 
Feb-07, 16 pts have received >8 weeks of treatment or have been taken 
off study for progressive disease. Toxicities consist of expected rates of 
rash and diarrhea. Responses: PR - 5; SD - 6; PD - 5; 4 pts are too early 
to assess (4 weeks only). Thus 11 of 16 (69%) have not progressed at 8 
weeks. All pts had fresh tumour samples collected. Laser microdissec-
tion and tumour DNA extraction was performed and genomic analysis 
is underway.
Summary: In this clinically selected population treated with ﬁrst-line 
erlotinib, the rate of non-progression at 8 weeks is acceptable. A unique 
correlation of extensive molecular data obtained from fresh tumour 
samples, data on pre-drug genetic abnormalities and post-drug clinical 
response, time to progression, and survival will be performed in all 
patients enrolled in this study. This work represents an effort to go 
beyond EGFR analysis and uncover novel features of the lung cancer 
genome that may help predict drug response and further understanding 
of tumour biology.
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Background: Geﬁtinib is a selective inhibitor of the epidermal growth 
factor (EGFR) tyrosine kinase and approved for use as salvage therapy 
in advanced non-small cell lung cancer (NSCLC). We retrospectively 
analyzed 359 Korean NSCLC patients treated with geﬁtinib to identify 
clinicopathologic parameters predictive of response and survival 
beneﬁt. 
Methods: Data from NSCLC patients treated with geﬁtinib at Samsung 
Medical Center in Korea from Jan 2003 until Dec 2005 were collected. 
Patients were treated with geﬁtinib 250mg per day until progression 
or development of toxicity. Response evaluation with spiral CT scan 
was performed at 4-8 weeks after geﬁtinib treatment. Multivariate Cox 
regression hazards analysis was performed to determine the combined 
effects of clinicopathological variables in relation to tumor response 
and overall survival.
Results: For 331 evaluable patients the overall response rate was 
25.1% (83/331; 3 CR, 80 PR) and disease control rate was 48.6%. 
Median age was 60 years (range 25-86). 236 patients (65.7%) were 
male and 154 patients (42.9%) were never-smokers. The most com-
mon histological subtype was adenocarcinoma (67.1%) and 183 
patients(51.0%) had a PS≥2. In a large majority of case (90.0%), 
cytotoxic chemotherapy had been administered before treatment of 
geﬁtinib and most of them received platinum-based combination 
regimens(84.4%) as the ﬁrst-line treatment. At a median follow-up of 
30 months, the median survival for all the 359 patients from the date 
of geﬁtinib administration was 6.2 months with 1 year-survival rate of 
32.2%. The median survival time calculated from the ﬁrst diagnosis of 
advanced/metastatic or recurrent disease was 19.7 months. Good per-
formance status (PS 0-1), never-smoker and development of skin rash 
after administration of geﬁtinib were statistically signiﬁcant favorable 
predictive markers for tumor response by multivariate analysis. Sig-
niﬁcant predictors for favorable survival were good performance status 
